VEGFA and neoplasm: Vascular endothelial growth factor (VEGF) targeted therapy disrupts tumor vasculature as well as inhibits angiogenesis, which have been exemplified by the first approved bevacizumab (Avastin) for metastatic colon cancer (mCRC) (39, 40).